Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Serum Bicarbonate and Structural and Functional Cardiac Abnormalities in Chronic Kidney Disease - A Report from the Chronic Renal Insufficiency Cohort Study.

Dobre M, Roy J, Tao K, Anderson AH, Bansal N, Chen J, Deo R, Drawz P, Feldman HI, Hamm LL, Hostetter T, Kusek JW, Lora C, Ojo AO, Shrama K, Rahman M; CRIC Study Investigators.

Am J Nephrol. 2016;43(6):411-20. doi: 10.1159/000446860. Epub 2016 May 28.

PMID:
27241893
2.

Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials.

Zhao YT, Li PY, Zhang JQ, Wang L, Yi Z.

Medicine (Baltimore). 2016 May;95(18):e3600. doi: 10.1097/MD.0000000000003600.

3.

Targeting heart failure with preserved ejection fraction: current status and future prospects.

Kanwar M, Walter C, Clarke M, Patarroyo-Aponte M.

Vasc Health Risk Manag. 2016 Apr 15;12:129-41. doi: 10.2147/VHRM.S83662. eCollection 2016. Review.

4.

MicroRNA and Heart Failure.

Wong LL, Wang J, Liew OW, Richards AM, Chen YT.

Int J Mol Sci. 2016 Apr 6;17(4):502. doi: 10.3390/ijms17040502. Review.

5.

Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.

van Giessen A, Boonman-de Winter LJ, Rutten FH, Cramer MJ, Landman MJ, Liem AH, Hoes AW, Koffijberg H.

Cardiovasc Diabetol. 2016 Mar 22;15:48. doi: 10.1186/s12933-016-0363-z.

6.

Recent advances in treatment of heart failure.

Kitai T, Tang WW.

F1000Res. 2015 Dec 18;4. pii: F1000 Faculty Rev-1475. doi: 10.12688/f1000research.7022.1. eCollection 2015. Review.

7.

Understanding heart failure with preserved ejection fraction: where are we today?

van Heerebeek L, Paulus WJ.

Neth Heart J. 2016 Apr;24(4):227-36. doi: 10.1007/s12471-016-0810-1. Review.

8.

2013 Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations.

Shin J, Park JB, Kim KI, Kim JH, Yang DH, Pyun WB, Kim YG, Kim GH, Chae SC; Guideline Committee of the Korean Society of Hypertension.

Clin Hypertens. 2015 Apr 15;21:3. doi: 10.1186/s40885-014-0014-1. eCollection 2015.

9.

Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction.

Samson R, Jaiswal A, Ennezat PV, Cassidy M, Le Jemtel TH.

J Am Heart Assoc. 2016 Jan 25;5(1). pii: e002477. doi: 10.1161/JAHA.115.002477. No abstract available.

10.

Towards 'Eternal Youth' of cardiac and skeletal muscle.

Yacoub M, ElGuindy A, ElGuindy A.

Glob Cardiol Sci Pract. 2015 Apr 21;2015:12. doi: 10.5339/gcsp.2015.12. eCollection 2015. No abstract available.

11.

Breakthrough in heart failure with preserved ejection fraction: are we there yet?

Lim SL, Lam CS.

Korean J Intern Med. 2016 Jan;31(1):1-14. doi: 10.3904/kjim.2016.31.1.1. Epub 2015 Dec 28. Review.

12.

Recent Patient Characteristics and Medications at Admission and Discharge in Hospitalized Patients With Heart Failure.

Arimura T, Miura S, Morito N, Shiga Y, Kitajima K, Morii J, Iwata A, Fujimi K, Yahiro E, Saku K.

J Clin Med Res. 2016 Feb;8(2):97-104. doi: 10.14740/jocmr2402w. Epub 2015 Dec 28.

13.

Mesenchymal stem cell-derived inflammatory fibroblasts mediate interstitial fibrosis in the aging heart.

Trial J, Entman ML, Cieslik KA.

J Mol Cell Cardiol. 2016 Feb;91:28-34. doi: 10.1016/j.yjmcc.2015.12.017. Epub 2015 Dec 22. Review.

PMID:
26718722
14.

New Insights in the Diagnosis and Treatment of Heart Failure.

Agnetti G, Piepoli MF, Siniscalchi G, Nicolini F.

Biomed Res Int. 2015;2015:265260. doi: 10.1155/2015/265260. Epub 2015 Oct 26. Review.

15.

Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices.

Wu CK, Su MY, Lee JK, Chiang FT, Hwang JJ, Lin JL, Chen JJ, Liu FT, Tsai CT.

Sci Rep. 2015 Nov 19;5:17007. doi: 10.1038/srep17007.

16.

Evidence of microvascular dysfunction in heart failure with preserved ejection fraction.

Lee JF, Barrett-O'Keefe Z, Garten RS, Nelson AD, Ryan JJ, Nativi JN, Richardson RS, Wray DW.

Heart. 2015 Nov 13. pii: heartjnl-2015-308403. doi: 10.1136/heartjnl-2015-308403. [Epub ahead of print]

PMID:
26567228
17.

Lysophosphatidic acid enhances survival of human CD34(+) cells in ischemic conditions.

Kostic I, Fidalgo-Carvalho I, Aday S, Vazão H, Carvalheiro T, Grãos M, Duarte A, Cardoso C, Gonçalves L, Carvalho L, Paiva A, Ferreira L.

Sci Rep. 2015 Nov 10;5:16406. doi: 10.1038/srep16406.

18.

Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction.

Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E; NHLBI Heart Failure Clinical Research Network.

N Engl J Med. 2015 Dec 10;373(24):2314-24. doi: 10.1056/NEJMoa1510774. Epub 2015 Nov 8.

19.

Renin-Angiotensin Activation and Oxidative Stress in Early Heart Failure with Preserved Ejection Fraction.

Negi SI, Jeong EM, Shukrullah I, Veleder E, Jones DP, Fan TH, Varadarajan S, Danilov SM, Fukai T, Dudley SC Jr.

Biomed Res Int. 2015;2015:825027. doi: 10.1155/2015/825027. Epub 2015 Oct 4.

20.

Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review.

Pandey A, Garg S, Matulevicius SA, Shah AM, Garg J, Drazner MH, Amin A, Berry JD, Marwick TH, Marso SP, de Lemos JA, Kumbhani DJ.

J Am Heart Assoc. 2015 Oct 12;4(10):e002137. doi: 10.1161/JAHA.115.002137. Review.

Items per page

Supplemental Content

Write to the Help Desk